J&J in Belgium invites you to the R&D Symposium on Antibody Conjugates
Johnson & Johnson in Belgium invites you to a one-day symposium to explore exciting advances in the discovery and development of antibody conjugates. From next-generation antibody-drug conjugates and radioligand therapies, innovation in ADC/RLT design and development to clinical studies, we will discuss success stories and future perspectives with leaders from both academia and industry.
- When? Thursday, June 19, 2025, from 9 AM - 5.30 PM
- Where? Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium
- For who? Researchers, clinicians, and industry leaders active in the antibody conjugate space
Our confirmed speakers: Alain Beck (Pierre Fabre Laboratories, France), Robin Carr (Myricx Bio, United Kingdom), David Planchard (Institut Gustave Roussey, France), Philipp R. Spycher (Araris Biotech AG, Switzerland), Marc Robillard (Tagworks Pharmaceuticals, Netherlands), David Klauber (AstraZeneca, United Kingdom), Ken Herrmann (University of Duisburg-Essen, Germany), Danielle Park (Novartis, Switzerland), Anne-Marie Dingemans (Erasmus University Rotterdam, Netherlands), Gunhild von Amsberg (University of Hamburg, Germany), Josh Lauring (J&J, USA) and Jacqueline Kinyamu-Akunda (J&J, USA).
Registration is free, but seats are limited. Register now to secure your spot.